Since activation of AKT is shown to be related to PARPi resistance in recent studies, there are some ongoing trials trying to combine PI3K/AKT/mTOR inhibitors and PARPi in gynecologic cancers [111] (Table 2). The gene discussed is AKT1; the disease is female reproductive organ cancer.